CPNG

Coupang Inc

13.90

Oct 23 • 3:59 PM ET -0.09 (-0.64%)

13.91

Aftermarket • 7:44 PM ET +0.01 (0.07%)

Consumer Cyclical Internet Retail USA Large NYSE

Peers: JD AMZN SE MELI PDD DASH BABA CART EBAY WMT

| Held by: VXF IWP IWR IWF SCHG VONG ITOT SCHX VT IWB

Index	-
Market Cap	24.99B
Enterprise Value	24.41B
Income	-767.00M
Sales	35.46B
Book/sh	1.67
Cash/sh	3.45
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	108000
IPO	Mar 11, 2021

P/E	-
Forward P/E	43.94
PEG	0.51
P/S	0.70
P/B	8.34
P/C	4.03
P/FCF	297.87
EV/EBITDA	-
EV/Sales	0.69
Quick Ratio	0.68
Current Ratio	0.87
Debt/Eq	1.89
LT Debt/Eq	1.03
Option/Short	Yes / Yes

EPS (ttm)	-0.43
EPS next Y	0.32
EPS next Q	-0.09
EPS this Y	-583.66%
EPS next Y	159.46%
EPS next 5Y	86.30%
EPS past 3/5Y	- -
Sales past 3/5Y	18.83% 23.61%
EPS Y/Y TTM	-309.73%
Sales Y/Y TTM	9.92%
EPS Q/Q	-1941.86%
Sales Q/Q	3.89%
Earnings	Nov 03 AMC
EPS/Sales Surpr.	-19.00% -0.74%

Insider Own	29.32%
Insider Trans	-0.04%
Inst Own	55.99%
Inst Trans	-2.93%
ROA	-4.35%
ROE	-19.99%
ROIC	-12.63%
Gross Margin	28.35%
Oper. Margin	-1.77%
Profit Margin	-2.16%
SMA20	-3.47%
SMA50	-7.26%
SMA200	-20.40%
Trades

Shs Outstand	1.63B
Shs Float	1.27B
Short Float	6.23%
Short Ratio	4.79
Short Interest	79.13M
52W High	32.35 -57.03%
52W Low	13.35 4.12%
Volatility	2.96% 3.43%
ATR (14)	0.51
RSI (14)	40.80
Beta	1.16
Rel Volume	0.56
Avg Volume	16.51M
Volume	9,211,578

Perf Week	-2.59%
Perf Month	0.14%
Perf Quarter	-12.74%
Perf Half Y	-32.23%
Perf YTD	-41.08%
Perf Year	-55.39%
Perf 3Y	-21.47%
Perf 5Y	-52.07%
Perf 10Y	-
Recom	1.55
Target Price	23.25
Prev Close	13.99
Price	13.90
Change %	-0.64%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-05-26	Upgrade	Deutsche Bank	Hold → Buy	$21.50
Jun-15-26	Initiated	CLSA	Outperform	$24
May-06-26	Downgrade	Deutsche Bank	Buy → Hold	$23
May-06-26	Downgrade	Citigroup	Buy → Neutral	$22.20
Feb-05-26	Initiated	Bernstein	Underperform	$17
Jan-16-26	Upgrade	Deutsche Bank	Hold → Buy	$25
Jan-12-26	Downgrade	Nomura	Buy → Neutral	$22
Sep-18-25	Initiated	Arete	Buy	$40
Aug-06-25	Upgrade	Nomura	Neutral → Buy	$35
Aug-06-25	Downgrade	Deutsche Bank	Buy → Hold	$27
Feb-26-25	Upgrade	Deutsche Bank	Hold → Buy	$28.50
Oct-07-24	Upgrade	Bernstein	Underperform → Outperform	$30
Sep-04-24	Upgrade	CLSA	Hold → Outperform	$18 → $31
May-16-24	Upgrade	UBS	Neutral → Buy	$26
May-03-24	Resumed	BofA Securities	Buy	$30
Apr-15-24	Upgrade	Citigroup	Neutral → Buy	$19 → $26
Feb-29-24	Upgrade	Deutsche Bank	Hold → Buy	$18.50 → $21
Jan-16-24	Downgrade	Citigroup	Buy → Neutral	$20 → $17
Dec-20-23	Downgrade	UBS	Buy → Neutral	$26 → $18.50
Aug-09-23	Downgrade	Deutsche Bank	Buy → Hold	$20

Show Previous Ratings

Oct-22-26 08:00AM	Sartori Cheese Boosts Wisconsin Dairy Exports to South Korea with Coupang (Business Wire)
Oct-20-26 04:05PM	Coupang to Announce Third Quarter 2026 Results on November 3, 2026 (Business Wire)
Oct-05-26 11:40AM	What Could Send MercadoLibre Stock Higher? (Trefis)
Sep-22-26 08:00AM	Montana 'Exporter of the Year' Proves Global Trade Drives Local Success (Business Wire)
Sep-21-26 03:20PM	Is MercadoLibre Stock As Cheap As Its Cash Says? (Trefis)
09:31AM	Loading…
Aug-18-26 09:31AM	Farfetch Names Manny Suero VP of Private Client Americas (WWD)
06:48AM	Trump Plays Kim Jong Un Card to Pressure South Korea Over Trade (Bloomberg)
Aug-12-26 06:36PM	The Market Is Paying You To Own MELI. Why? (Trefis)
Aug-06-26 01:05AM	Pattern Group Inc (PTRN) (Q2 2026) Earnings Call Highlights: Record Revenue and NRR Fuel Raised ... (GuruFocus.com)
Aug-05-26 08:17AM	Coupang Swings to a $556 Million Loss on Korean Fines (GuruFocus.com)
06:52AM	Coupang shares slide after revenue miss and cautious outlook disappoint investors (InvestorsHub)
Aug-04-26 04:05PM	Coupang Announces Results for Second Quarter 2026 (Business Wire)
Jul-30-26 07:42AM	Why MELI Beats A Bond At Its Own Game (Trefis) +6.13%
Jul-28-26 11:28AM	U.S. Tech Company Coupang Inc. Named to 2026 Fortune Global 500 for the First Time, Bolstered by AI-Powered Global Commerce Investments (Business Wire)
Jul-21-26 04:05PM	Coupang to Announce Second Quarter 2026 Results on August 4, 2026 (Business Wire)
06:07PM	Loading…
Jul-20-26 06:07PM	Coupang Warehouse Fire Could Cost Hundreds of Millions in Losses (Sourcing Journal)
Jul-14-26 01:45AM	South Korean court suspends FTC designation Coupang founder Kim Bom as controlling entity (Reuters)
Jul-13-26 08:32AM	The Real Risk Inside MercadoLibre Stock (Trefis)
Jul-07-26 08:04AM	Why MELI Beats A Bond At Its Own Game (Trefis)
Jul-02-26 12:23PM	U.S. Congress Accuses South Korea of Targeting Coupang (GuruFocus.com)
06:01AM	South Korea disputes US congressional report claiming discrimination against Seattle-based Coupang (Associated Press)
04:47AM	CPNG Stock In Focus: U.S. House Report Accuses South Korea Of Targeting Coupang After Data Breach (Stocktwits)
Jun-18-26 01:25PM	The 25 Biggest U.S. IPOs of All Time (Kiplinger)
Jun-12-26 10:31AM	South Korea issues Won624.68bn fine on Coupang over data breach (Retail Insight Network)
Jun-11-26 07:57PM	CPNG Stock Surges In Best Day Since Late 2022 As Coupang Data Breach Fine Lands Milder Than Expected (Stocktwits) +14.09%
09:51AM	Coupang Hit With Record $409 Million Fine (GuruFocus.com)
09:18AM	South Korea hits Coupang with $400M+ fine for data breach that affected millions (TechCrunch)
04:50AM	South Korea fines Coupang in country's largest data breach penalty (Reuters Videos)
01:53AM	South Korea Fines Coupang $410 Million Over Data Breach (The Wall Street Journal)
12:37AM	South Koreas Amazon hit with record fine over data breach (Financial Times)
11:22PM	Loading…
Jun-10-26 11:22PM	S.Korea hits Coupang with record fine over e-commerce data leak (AFP)
11:21PM	South Korea fines Coupang $409 million in country's largest data breach penalty (Reuters)
Jun-03-26 12:00PM	Coupang Jumps to No. 132 on Fortune 500 as the Company Scales AI-Driven Global Commerce (Business Wire)
May-26-26 10:13AM	South Koreas online retail crosses 60% share for first time (Retail Insight Network)
08:48AM	Bernstein questions Uber capital allocation in potential Delivery Hero acquisition (Investing.com)
May-14-26 08:30AM	WV-Based Family Business Expands Globally with Coupang (Business Wire)
May-09-26 07:17PM	Coupang Taiwan reveals 2025 data breach affecting 33.7 million accounts, launches bug bounty program (DigiTimes)
May-07-26 02:47PM	Coupang Slides 7% After $242 Million Loss And Slower Growth Warning (GuruFocus.com)
May-05-26 04:05PM	Coupang Announces Results for First Quarter 2026 (Business Wire) -13.82%
Apr-24-26 06:46AM	Tradr Launches Leveraged ETFs on AXTI, CPNG, MPWR and STX (Business Wire)
Apr-23-26 03:00PM	Tradr Set to Launch Leveraged ETFs on AXTI, CPNG, MPWR and STX (Business Wire)
Apr-14-26 02:41PM	Coupang Announces $84M in investments for Global AI Tech Startups (Business Wire)
01:17PM	Trump's Fed Chair Nominee Earned Millions From Investment Firms. New Filings Detail His Wealth. (Barrons.com)
Apr-02-26 04:21PM	Brokers Suggest Investing in Coupang (CPNG): Read This Before Placing a Bet (Quartz)
Mar-18-26 11:17AM	Los Angeles Small Business Spreads Global Reach with Coupang (Business Wire)
Mar-17-26 08:36PM	Coupang NVIDIA Collaboration on AI Factory Is Powering the Future of E-Commerce Logistics (Business Wire)
Mar-12-26 10:51AM	DoorDash Stock: Is DASH Underperforming the Consumer Cyclical Sector? (Barchart)
Mar-10-26 01:45AM	Barclays Raises PT on Coupang, Inc. (CPNG) to $24 (Insider Monkey)
Mar-08-26 12:02PM	Coupang (CPNG) Q4 2025 Earnings Impacted by Data Incident Involving 33M Accounts (Insider Monkey)
06:19AM	Morgan Stanley Maintains Overweight Rating on Coupang (CPNG) (Insider Monkey)
Mar-05-26 09:13AM	Should You Hold Coupang (CPNG)? (Insider Monkey)
Mar-04-26 07:30PM	E-commerce Giant Coupang Moves to Build Stablecoin Legal Team (BeInCrypto)
07:10AM	U.S. Tech Company Coupang Named a 2026 LexisNexis Top 100 Global Innovator (Business Wire)
Mar-03-26 09:30AM	Wall Street Bulls Look Optimistic About Coupang (CPNG): Should You Buy? (Zacks)
Mar-02-26 09:00AM	Is Trending Stock Coupang, Inc. (CPNG) a Buy Now? (Zacks)
Mar-01-26 06:43PM	Analyst Report: Coupang, Inc. (Morningstar Research)
09:58AM	Coupang (CPNG) Records $8.8B Q4 Revenue, $26M Loss Amid Data Breach Backlash (Insider Monkey)
Feb-27-26 09:14PM	Coupang Q4 Earnings Call Highlights (MarketBeat)
12:21PM	Coupang Q4 Earnings Miss Estimates, Revenues Increase Y/Y, Stock Down (Zacks)
12:08AM	Coupang Inc (CPNG) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges (GuruFocus.com)
Feb-26-26 08:00PM	Coupang (CPNG) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:00PM	Coupang, Inc. (CPNG) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:30PM	Coupang (NYSE:CPNG) Misses Q4 CY2025 Revenue Estimates (StockStory)
04:13PM	Coupang swings to loss as data breach dents Q4; sees muted near-term growth (Reuters)
04:13PM	Coupang reports Q4 revenue of $8.8 billion, missing analyst expectations (Reuters)
04:05PM	Coupang Announces Results for Fourth Quarter 2025 (Business Wire)
Feb-25-26 10:05PM	South Korea watchdog fines Coupang $1.6 million for pressuring suppliers, delaying payments (Reuters)
06:05PM	Coupang braces for increased competition amid fallout from South Korea data breach (Reuters)
06:18AM	Is Coupang (CPNG) One of the Best High Volume Stocks to Invest In Now? (Insider Monkey)
Feb-24-26 10:12PM	Coupang (CPNG) Reports Q4: Everything You Need To Know Ahead Of Earnings (StockStory)
09:53AM	Coupang Set to Report Q4 Earnings: What's in Store for the Stock? (Zacks)
Feb-23-26 10:33AM	Nvidia, Joby, CoreWeave, Lucid and More Stocks with Earnings This Week (Benzinga)
Feb-19-26 05:50PM	Coupang, Inc. (CPNG) Rises As Market Takes a Dip: Key Facts (Zacks)
10:00AM	Earnings Preview: Coupang, Inc. (CPNG) Q4 Earnings Expected to Decline (Zacks)
09:30AM	Travelzoo (TZOO) Reports Break-Even Earnings for Q4 (Zacks)
Feb-17-26 06:00PM	Coupang, Inc. (CPNG) Outperforms Broader Market: What You Need to Know (Zacks)
06:30AM	Pennsylvania Small Businesses Expand into Global Markets With Assist from Coupang (Business Wire)
Feb-16-26 09:00AM	Coupang, Inc. (CPNG) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Feb-14-26 01:19AM	Coupang (CPNG) Maintained at Buy With $24 PT (Insider Monkey)
Feb-13-26 04:52PM	Analyst Report: Coupang, Inc. (Morningstar Research)
09:30AM	Wall Street Analysts Think Coupang (CPNG) Is a Good Investment: Is It? (Zacks)
Feb-12-26 04:05PM	Coupang to Announce Fourth Quarter 2025 Results on February 26, 2026 (Business Wire)
02:24PM	SoftBank Vision Fund Posts $2.4 Billion Quarterly Gain (GuruFocus.com)
11:56AM	More US investors sue South Korean government over handling of Coupang data breach (TechCrunch)
02:40AM	SoftBank Swings to Profit on Valuation Boost From OpenAI Bet (Bloomberg)
Feb-11-26 08:57PM	More investors join legal challenge against South Korea over Coupang data leak handling (Reuters)
09:45AM	Abrams Capital, Durable Capital Partners, and Foxhaven Join Greenoaks and Altimeter in Legal Effort to End Korea's Discrimination Against U.S. Companies and Uphold U.S.-Korea Trade Commitments (Business Wire)
Feb-10-26 05:50PM	Coupang, Inc. (CPNG) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
06:41AM	Bernstein Initiates Coverage of Coupang (CPNG) With an Underperform Rating (Insider Monkey)
06:41AM	South Korea Cites Key Failures in Coupang Data Breach (GuruFocus.com)
12:16AM	South Korea blames Coupang data breach on management failure, not sophisticated attack (Reuters)
Feb-09-26 12:05PM	Bernstein Initiates Coupang (CPNG) Coverage with Underperform Rating, $17 PT (Insider Monkey)
Feb-08-26 11:03PM	2 Reasons to Like CPNG (and 1 Not So Much) (StockStory)
Feb-05-26 11:59PM	BYDs $60 Billion Wipeout Points to Deeper Turmoil for China EVs (Bloomberg) -13.68% +5.54%
10:41AM	Coupang, Inc. (CPNG)'s Growth Engine Remains Intact Despite Temporary Uncertainty (Insider Monkey)
10:12AM	Microsoft downgraded, Snap upgraded: Wall Street's top analyst calls (The Fly)
07:58AM	Here Are Thursdays Top Wall Street Analyst Research Calls: CAVA Group, DigitalOcean, Fox Corp, Jack Henry, Microsoft, Qualcomm, Snap, Zoom Communications, and More (24/7 Wall St.)
03:58AM	Coupang confirms more data leaks which South Korean aide says has 'shaken' US ties (Reuters)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lee Jonathan D.	Chief Accounting Officer	Oct 02 '26	Sale	13.65	5,519	75,339	176,396	Oct 05 05:38 PM
Jonathan Lee	Officer	Oct 02 '26	Proposed Sale	13.65	5,519	75,339		Oct 02 04:38 PM
Rogers Harold	See Remarks	Aug 10 '26	Sale	16.18	192,110	3,107,975	740,931	Aug 11 04:39 PM
Lee Jonathan D.	Chief Accounting Officer	Aug 10 '26	Sale	16.10	5,519	88,867	181,915	Aug 11 04:36 PM
Jonathan Lee	Officer	Aug 10 '26	Proposed Sale	16.10	5,519	88,867		Aug 10 04:25 PM
Harold Rogers	Officer	Aug 10 '26	Proposed Sale	16.18	192,110	3,107,973		Aug 10 04:25 PM
Kevin M Warsh	Former Director	May 19 '26	Proposed Sale	15.62	356,739	5,572,263		May 19 04:00 PM
Kevin M Warsh	Former Director	May 15 '26	Proposed Sale	16.43	102,363	1,681,998		May 15 05:10 PM
MEHTA NEIL	Director	Mar 12 '26	Buy	18.68	3,000,000	56,036,100	52,978,114	Mar 13 09:04 PM
MEHTA NEIL	Director	Mar 13 '26	Buy	18.40	2,332,863	42,923,279	55,310,977	Mar 13 09:04 PM
MEHTA NEIL	Director	Mar 11 '26	Buy	18.64	2,017,241	37,603,591	49,978,114	Mar 13 09:04 PM
Lee Jonathan D.	Chief Accounting Officer	Jan 02 '26	Sale	23.62	2,679	63,278	122,096	Jan 02 04:51 PM
Jonathan Lee	affiliate	Jan 02 '26	Proposed Sale	23.62	2,679	63,278		Jan 02 04:07 PM
Pranam Kolari	Former Officer	Nov 17 '25	Proposed Sale	28.20	27,388	772,209		Nov 17 04:19 PM
Anand Gaurav	Chief Financial Officer	Nov 10 '25	Sale	29.02	75,350	2,186,619	1,941,590	Nov 12 04:34 PM
GAURAV ANAND	Officer	Nov 10 '25	Proposed Sale	28.88	75,350	2,176,108		Nov 10 04:34 PM
Kolari Pranam	VP, Search and Recommendations	Nov 03 '25	Sale	31.98	11,653	372,608	147,023	Nov 05 04:24 PM
Pranam Kolari	Officer	Nov 03 '25	Proposed Sale	31.98	11,653	372,608		Nov 03 04:15 PM

Coupang, Inc. engages in the provision of retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Coupang Play, and Farfetch. It operates through the Product Commerce and Developing Offerings segments. The Product Commerce segment consists of the company's core retail and marketplace offerings and Rocket Fresh, its fresh grocery category offering. It also includes advertising products associated with these offerings. The Developing Offerings segment covers the company's more nascent offerings and services including: Coupang Eats, a restaurant ordering and delivery service in Korea, Coupang Play, an online content streaming service in Korea, fintech services, retail operations in Taiwan, as well as advertising products associated with these offerings. It also includes Farfetch, a global luxury fashion marketplace. The company was founded by Bom Kim in 2010 and is headquartered in Seattle, WA.

FounderMr. Bom Kim

Chief Financial OfficerMr. Gaurav Anand

General Counsel & Chief Administrative OfficerMr. Harold L. Rogers J.D.

Chief Accounting OfficerMr. Jonathan Lee

Vice President of Investor RelationsMr. Michael Parker

Open in Screener

ROIV

Roivant Sciences Ltd

36.49

Oct 23 • 3:59 PM ET -0.96 (-2.56%)

36.69

Aftermarket • 7:30 PM ET +0.20 (0.54%)

Healthcare Biotechnology United Kingdom Large NASD

ROIV Roivant Sciences Ltd daily Stock Chart

Peers: ARGX INCY BBIO ALNY ABVX INSM REGN MRNA VRTX IONS

| Held by: IJH VTI VB XMMO VBK VXF MDY IBB XBI SPMD

Index	-
Market Cap	26.36B
Enterprise Value	23.31B
Income	-266.25M
Sales	7.53M
Book/sh	5.86
Cash/sh	5.32
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	721
IPO	Dec 08, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	3500.33
P/B	6.23
P/C	6.85
P/FCF	-
EV/EBITDA	-
EV/Sales	3095.48
Quick Ratio	16.72
Current Ratio	16.72
Debt/Eq	0.03
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-0.44
EPS next Y	-1.31
EPS next Q	-0.37
EPS this Y	-154.96%
EPS next Y	4.98%
EPS next 5Y	5.61%
EPS past 3/5Y	32.67% 34.68%
Sales past 3/5Y	-48.73% -19.07%
EPS Y/Y TTM	45.61%
Sales Y/Y TTM	-67.58%
EPS Q/Q	19.77%
Sales Q/Q	-33.55%
Earnings	Nov 09 BMO
EPS/Sales Surpr.	-11.72% -29.89%

Insider Own	27.42%
Insider Trans	-3.31%
Inst Own	76.34%
Inst Trans	3.25%
ROA	-5.15%
ROE	-6.21%
ROIC	-6.15%
Gross Margin	43.37%
Oper. Margin	-18146.12%
Profit Margin	-3534.96%
SMA20	3.30%
SMA50	-0.42%
SMA200	17.15%
Trades

Shs Outstand	722.67M
Shs Float	524.29M
Short Float	7.50%
Short Ratio	5.31
Short Interest	39.30M
52W High	42.50 -14.14%
52W Low	17.89 103.97%
Volatility	4.54% 3.63%
ATR (14)	1.43
RSI (14)	53.35
Beta	1.23
Rel Volume	1.11
Avg Volume	7.41M
Volume	8,217,197

Perf Week	8.83%
Perf Month	1.00%
Perf Quarter	5.10%
Perf Half Y	33.13%
Perf YTD	68.16%
Perf Year	101.38%
Perf 3Y	324.55%
Perf 5Y	436.62%
Perf 10Y	-
Recom	1.40
Target Price	48.91
Prev Close	37.45
Price	36.49
Change %	-2.56%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-12-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Sep-17-26	Initiated	Stifel	Buy	$51
Mar-20-26	Initiated	Bernstein	Outperform	$35
Sep-02-25	Initiated	Citigroup	Buy	$16
Jul-10-25	Resumed	Goldman	Buy	$19
Feb-15-24	Initiated	Wolfe Research	Outperform	$17
Jan-05-24	Initiated	Piper Sandler	Overweight	$20
Dec-12-23	Initiated	Deutsche Bank	Buy	$14
Oct-17-23	Initiated	Guggenheim	Buy	$17
Jun-08-23	Initiated	BofA Securities	Neutral	$10.50
Oct-27-22	Initiated	JP Morgan	Overweight	$7
May-23-22	Initiated	SVB Leerink	Outperform	$6
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-15-21	Initiated	Goldman	Buy	$15
Nov-08-21	Initiated	H.C. Wainwright	Buy	$14
Oct-28-21	Initiated	Citigroup	Buy	$11
Oct-26-21	Initiated	Truist	Buy	$15
Oct-26-21	Initiated	Jefferies	Buy	$10
Oct-26-21	Initiated	Cowen	Outperform

Show Previous Ratings

Oct-21-26 09:09AM	Roivant Sciences stock surges on positive uveitis trial data (Investing.com) +5.38%
07:00AM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 (GlobeNewswire)
07:00AM	Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU) (GlobeNewswire)
Oct-08-26 01:33PM	IMVT, ROIV Stocks Slide As Argenx Sjögrens Trial Failure Hits Drug Class (Stocktwits)
Sep-23-26 08:12AM	Roivant's Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss (InvestorsHub)
07:00AM	Loading…
07:00AM	Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus (GlobeNewswire)
Sep-10-26 07:55AM	Podcast: key readouts from ESC and ERS (Pharmaceutical Technology)
Sep-08-26 11:00PM	Why Did DELL, ROIV, SHEL Stocks Surge To 52-Week Highs Today? (Stocktwits) +18.75%
01:53PM	These 2 Biotech Stocks Hit Record Highs Today Whats Driving The Rallies? (Stocktwits)
12:36PM	Roivant Sciences Stock Soars as Lung Disease Drug Hits Goals (Barrons.com)
11:18AM	Why These Two Hot Biotech Stocks Just Surged To Record Highs (Investor's Business Daily)
07:51AM	Roivants Experimental Lung Disease Drug Hits Key Phase 2 Goal ROIV Stock Tracks All-Time High (Stocktwits)
06:55AM	Roivant Sciences Shares Rise After Phase 2 Mosliciguat Results (InvestorsHub)
06:00AM	Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study (GlobeNewswire)
Sep-06-26 01:00AM	Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call (GlobeNewswire)
03:29PM	Loading…
Aug-27-26 03:29PM	Roivant Announces FDA Approval of LISRAYA (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. (GlobeNewswire)
03:28PM	Priovant Announces FDA Approval of LISRAYA (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. (GlobeNewswire)
Aug-26-26 11:11AM	JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis (GlobeNewswire)
Aug-06-26 03:02PM	Roivant Sciences Ltd (ROIV) (Q1 2026) Earnings Call Highlights: Strategic Advances and Strong ... (GuruFocus.com)
07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update (GlobeNewswire)
07:00AM	Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS) (GlobeNewswire)
Jul-23-26 04:05PM	Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 (GlobeNewswire)
Jul-07-26 02:28PM	ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week (Stocktwits)
May-20-26 03:00PM	Roivant Sciences Ltd (ROIV) Q4 2025 Earnings Call Highlights: Strategic Settlements and ... (GuruFocus.com) +14.89%
01:20PM	Can a New Arthritis Drug Make Immunovant the Next Biotech Star? (Barrons.com)
11:38AM	2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug (Barrons.com)
08:45AM	Roivant Shares Climb on Earnings Beat Despite Revenue Shortfall (ROIV) (InvestorsHub)
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update (GlobeNewswire)
May-11-26 04:05PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026 (GlobeNewswire)
Apr-02-26 05:00AM	Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) (GlobeNewswire)
05:00AM	Loading…
05:00AM	Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) (GlobeNewswire)
Mar-28-26 03:00PM	New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis (GlobeNewswire)
Mar-04-26 04:04PM	Moderna Stock Pops After Inking $950 Million Covid Vaccine Settlement (Investor's Business Daily) +6.00%
02:35PM	Moderna Settles a Covid Vaccine Patent Lawsuit. What It Means for the Stock. (Barrons.com)
09:55AM	MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS (Zacks)
09:15AM	Stocks to Watch Wednesday: Coinbase, CrowdStrike, Gitlab, Moderna (The Wall Street Journal)
09:01AM	Moderna Pops After Inking $950 Million Covid Vaccine Settlement (Investor's Business Daily)
08:40AM	Moderna and Ross Stores Lead Stock Gainers on Wednesday (24/7 Wall St.)
08:14AM	Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars (Benzinga)
Mar-03-26 04:15PM	Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna (GlobeNewswire)
07:00AM	Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis (GlobeNewswire)
Feb-14-26 01:29AM	Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data (Insider Monkey)
Feb-10-26 06:41AM	TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV) - Here's Why (Insider Monkey)
Feb-08-26 08:39AM	Lumentum, Woodward, And Teradyne Are Among the Top 10 Large-Cap Gainers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio? (Benzinga)
Feb-07-26 06:38AM	Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress (Insider Monkey)
Feb-06-26 02:05PM	Roivant Stock Soars On Experimental Skin Drug Delivering 100% Response - Why It Matters (Benzinga) +22.14%
02:00PM	Roivant Sciences Ltd (ROIV) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com)
01:25PM	Tech Bounces As Software Sell-Off Eases, Dow Jones Hits Records: What's Moving Markets Friday? (Benzinga)
10:10AM	Roivant Sciences Q3 Earnings Call Highlights (MarketBeat)
10:03AM	Roivant Sciences Catapults On A 'Dream Scenario' For Its Blockbuster Hopeful (Investor's Business Daily)
08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 (GlobeNewswire)
07:00AM	Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) (GlobeNewswire)
Feb-01-26 07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
Jan-23-26 04:15PM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 (GlobeNewswire)
Jan-20-26 10:31AM	Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report (Benzinga)
Jan-02-26 10:50AM	Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline (Insider Monkey)
Dec-22-25 08:10AM	Insider Action: Multimillion-dollar sell-offs across major U.S. companies (CNBC TV)
Dec-11-25 07:30AM	Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day (GlobeNewswire) +5.43%
Dec-10-25 02:00AM	A Roivant spinout bets on AI-designed drugs for immune conditions (BioPharma Dive)
02:00AM	A former Roivant spinout bets on AI-designed drugs for immune conditions (BioPharma Dive)
Nov-10-25 02:01PM	Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
08:25AM	Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update (GlobeNewswire)
Nov-06-25 09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-05-25 09:10AM	LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-04-25 07:30AM	Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)? (Insider Monkey)
Oct-27-25 04:10PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 (GlobeNewswire)
Oct-21-25 05:52AM	Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV) (Insider Monkey)
Oct-04-25 04:54PM	Roivant's Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints (Insider Monkey)
Sep-29-25 08:01PM	Vivek Ramaswamy's Bitcoin Play Just Got Bigger: This $1.3B Deal Could Signal Corporate Crypto's Next Phase (Benzinga)
Sep-23-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice (Zacks)
Sep-22-25 10:21AM	Ramaswamy-backed Strive to buy Semler in $1.3 billion deal all stock deal, boosting Bitcoin holdings (Reuters)
Sep-18-25 10:47AM	Roivant Sciences (ROIV) Hits New All-Time High as Drug Candidate Clinical Trial Posts Impressive Results (Insider Monkey)
10:34AM	Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains? (Zacks)
Sep-17-25 04:11PM	Roivant Flirts With A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease (Investor's Business Daily) +7.76%
12:49PM	Why Roivant Sciences Stock Is Soaring Today (Motley Fool)
07:00AM	Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) (GlobeNewswire)
Sep-14-25 04:00AM	Vivek Ramaswamy Sells $22.7 Million of Roivant Sciences Stock (Barrons.com)
Sep-11-25 04:30PM	Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List (GlobeNewswire)
11:11AM	Roivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for Mosliciguat (Insider Monkey)
Sep-03-25 01:01PM	Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients (GlobeNewswire)
Aug-28-25 11:49PM	Roivant Sciences (ROIV) Announces Q1 2025 Business Update (Insider Monkey)
Aug-12-25 06:42PM	Why Roivant Sciences Stock Bounced Back on Tuesday (Motley Fool)
03:02AM	Roivant Sciences Ltd (ROIV) Q1 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Aug-11-25 04:58PM	Why Roivant Sciences Stock Was Slipping on Monday (Motley Fool)
08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update (GlobeNewswire)
Aug-08-25 09:17AM	What To Expect From Roivant Sciences Ltd (ROIV) Q1 2026 Earnings (GuruFocus.com)
Aug-07-25 06:15PM	Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-05-25 08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Jul-28-25 04:05PM	Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025 (GlobeNewswire)
Jul-24-25 11:47PM	Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with 'Buy' Rating (Insider Monkey)
Jul-11-25 06:20AM	Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar? (Zacks)
Jun-24-25 12:45PM	Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat (Insider Monkey)
Jun-16-25 07:00AM	Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics (GlobeNewswire)
Jun-09-25 04:05PM	Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis (GlobeNewswire)
May-29-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +6.40%
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Venker Eric	President & Immunovant CEO	Oct 20 '26	Sale	35.11	200,000	7,022,668	1,399,154	Oct 22 06:44 PM
Venker Eric	Officer	Oct 20 '26	Proposed Sale	35.12	200,000	7,023,513		Oct 20 04:44 PM
Epperly Melissa B,	Director	Oct 01 '26	Option Exercise	4.46	17,750	79,165	32,704	Oct 05 06:05 PM
Epperly Melissa B,	Director	Oct 01 '26	Sale	36.10	17,750	640,861	14,954	Oct 05 06:05 PM
Venker Eric	President & Immunovant CEO	Sep 30 '26	Option Exercise	3.85	200,000	770,000	1,799,154	Oct 02 05:37 PM
Venker Eric	President & Immunovant CEO	Sep 30 '26	Sale	36.62	200,000	7,324,000	1,599,154	Oct 02 05:37 PM
Venker Eric	Officer	Sep 30 '26	Proposed Sale	36.62	200,000	7,323,556		Sep 30 04:21 PM
Epperly Melissa B,	Director	Sep 15 '26	Sale	39.74	4,938	196,230	9,900	Sep 17 06:43 PM
Fitzgerald Meghan	Director	Sep 15 '26	Sale	39.74	5,112	203,152	36,108	Sep 17 06:42 PM
MELISSA EPPERLY	Director	Sep 15 '26	Proposed Sale	41.02	22,688	930,662		Sep 15 04:40 PM
MEGHAN FITZGERALD	Officer	Sep 15 '26	Proposed Sale	41.02	5,112	209,694		Sep 15 04:32 PM
Fitzgerald Meghan	Director	Sep 08 '26	Option Exercise	8.80	20,000	176,000	62,963	Sep 10 09:00 PM
Fitzgerald Meghan	Director	Sep 08 '26	Sale	39.90	20,000	798,000	42,963	Sep 10 09:00 PM
MEGHAN FITZGERALD	Director	Sep 08 '26	Proposed Sale	34.93	20,000	698,600		Sep 08 04:27 PM
Venker Eric	President & Immunovant CEO	Aug 28 '26	Option Exercise	3.85	200,000	770,000	1,799,154	Sep 01 09:00 PM
Venker Eric	President & Immunovant CEO	Aug 28 '26	Sale	35.77	200,000	7,153,393	1,599,154	Sep 01 09:00 PM
Venker Eric	Officer	Aug 28 '26	Proposed Sale	35.74	200,000	7,147,088		Aug 28 04:33 PM
Sukhatme Mayukh	President & CIO	Aug 19 '26	Option Exercise	3.85	172,899	665,661	18,803,638	Aug 21 09:00 PM
Sukhatme Mayukh	President & CIO	Aug 21 '26	Option Exercise	3.85	144,756	557,311	18,775,495	Aug 21 09:00 PM
Sukhatme Mayukh	President & CIO	Aug 20 '26	Option Exercise	3.85	17,519	67,448	18,648,258	Aug 21 09:00 PM
Sukhatme Mayukh	President & CIO	Aug 19 '26	Sale	37.17	172,899	6,426,656	18,630,739	Aug 21 09:00 PM
Sukhatme Mayukh	President & CIO	Aug 21 '26	Sale	36.48	144,756	5,280,699	18,630,739	Aug 21 09:00 PM
Sukhatme Mayukh	President & CIO	Aug 20 '26	Sale	37.30	17,519	653,459	18,630,739	Aug 21 09:00 PM
MAYUKH SUKHATME	Officer	Aug 21 '26	Proposed Sale	36.48	144,756	5,280,004		Aug 21 04:20 PM
MAYUKH SUKHATME	Officer	Aug 20 '26	Proposed Sale	37.30	17,519	653,408		Aug 20 04:34 PM
MAYUKH SUKHATME	Officer	Aug 19 '26	Proposed Sale	37.17	172,899	6,426,357		Aug 19 04:23 PM
Sukhatme Mayukh	President & CIO	Aug 17 '26	Option Exercise	3.85	284,707	1,096,122	18,915,446	Aug 18 09:00 PM
Sukhatme Mayukh	President & CIO	Aug 14 '26	Option Exercise	3.85	243,177	936,231	18,873,916	Aug 18 09:00 PM
Sukhatme Mayukh	President & CIO	Aug 18 '26	Option Exercise	3.85	136,942	527,227	18,735,880	Aug 18 09:00 PM
Sukhatme Mayukh	President & CIO	Aug 17 '26	Sale	36.25	284,707	10,320,629	18,630,739	Aug 18 09:00 PM
Sukhatme Mayukh	President & CIO	Aug 14 '26	Sale	36.23	243,177	8,810,303	18,630,739	Aug 18 09:00 PM
Sukhatme Mayukh	President & CIO	Aug 18 '26	Sale	36.73	136,942	5,029,470	18,630,739	Aug 18 09:00 PM
MAYUKH SUKHATME	Officer	Aug 18 '26	Proposed Sale	36.73	136,942	5,029,209		Aug 18 04:29 PM
MAYUKH SUKHATME	Officer	Aug 17 '26	Proposed Sale	36.25	284,707	10,320,572		Aug 17 04:40 PM
MAYUKH SUKHATME	Officer	Aug 14 '26	Proposed Sale	36.23	243,177	8,809,768		Aug 14 04:20 PM
Venker Eric	President & Immunovant CEO	Jul 27 '26	Option Exercise	3.85	200,000	770,000	1,813,063	Jul 29 09:00 PM
Venker Eric	President & Immunovant CEO	Jul 27 '26	Sale	34.95	200,000	6,990,000	1,613,063	Jul 29 09:00 PM
Venker Eric	Officer	Jul 27 '26	Proposed Sale	34.95	200,000	6,989,924		Jul 27 04:16 PM
Fitzgerald Meghan	Director	Jun 30 '26	Option Exercise	8.80	10,000	88,000	52,963	Jul 02 07:03 PM
Fitzgerald Meghan	Director	Jun 30 '26	Sale	34.90	10,000	349,000	42,963	Jul 02 07:03 PM
Epperly Melissa B,	Director	Jun 29 '26	Option Exercise	4.46	17,750	79,165	34,224	Jul 01 06:34 PM
Epperly Melissa B,	Director	Jun 29 '26	Sale	34.38	17,750	610,252	16,474	Jul 01 06:34 PM
MANCHESTER KEITH S	Director	Jun 29 '26	Sale	34.55	800,000	27,642,000	13,701,546	Jun 30 08:38 PM
MANCHESTER KEITH S	Director	Jun 26 '26	Sale	34.00	625,783	21,275,309	14,501,546	Jun 30 08:38 PM
MANCHESTER KEITH S	Director	Jun 30 '26	Sale	35.45	200,000	7,090,000	1,748,403	Jun 30 08:38 PM
MANCHESTER KEITH S	Director	Jun 30 '26	Sale	35.28	12,380	436,766	13,689,166	Jun 30 08:38 PM
Gold Daniel Allen	Director	Jun 29 '26	Sale	34.55	800,000	27,642,000	13,701,546	Jun 30 08:30 PM
Gold Daniel Allen	Director	Jun 26 '26	Sale	34.00	625,783	21,275,309	14,501,546	Jun 30 08:30 PM
Gold Daniel Allen	Director	Jun 30 '26	Sale	35.28	12,380	436,766	13,689,166	Jun 30 08:30 PM
QVT Financial LP	Director by Deputization	Jun 29 '26	Sale	34.55	800,000	27,642,000	13,701,546	Jun 30 07:59 PM
QVT Financial LP	Director by Deputization	Jun 26 '26	Sale	34.00	625,783	21,275,309	14,501,546	Jun 30 07:59 PM
QVT Financial LP	Director by Deputization	Jun 30 '26	Sale	35.28	12,380	436,766	13,689,166	Jun 30 07:59 PM
MEGHAN FITZGERALD	Director	Jun 30 '26	Proposed Sale	34.73	10,000	347,300		Jun 30 04:36 PM
KEITH S MANCHESTER	Director	Jun 30 '26	Proposed Sale	35.45	200,000	7,090,280		Jun 30 04:25 PM
MELISSA EPPERLY	Director	Jun 29 '26	Proposed Sale	34.07	17,750	604,742		Jun 29 04:40 PM
Venker Eric	President & Immunovant CEO	Jun 24 '26	Option Exercise	3.85	200,000	770,000	1,813,063	Jun 26 06:13 PM
Venker Eric	President & Immunovant CEO	Jun 24 '26	Sale	33.16	200,000	6,631,268	1,613,063	Jun 26 06:13 PM
MAYUKH SUKHATME	Officer	Jun 26 '26	Proposed Sale	34.08	500,000	17,039,650		Jun 26 04:10 PM
MAYUKH SUKHATME	Officer	Jun 25 '26	Proposed Sale	34.13	500,000	17,066,500		Jun 25 04:33 PM
Venker Eric	Officer	Jun 24 '26	Proposed Sale	33.16	200,000	6,631,659		Jun 24 04:01 PM
Venker Eric	President & Immunovant CEO	May 22 '26	Option Exercise	3.85	200,000	770,000	1,813,063	May 22 06:25 PM
Venker Eric	President & Immunovant CEO	May 22 '26	Sale	30.27	200,000	6,054,000	1,613,063	May 22 06:25 PM
Venker Eric	Officer	May 22 '26	Proposed Sale	30.27	200,000	6,054,731		May 22 04:00 PM
Venker Eric	President & Immunovant CEO	Apr 20 '26	Option Exercise	3.85	200,000	770,000	1,847,546	Apr 22 06:27 PM
Venker Eric	President & Immunovant CEO	Apr 20 '26	Sale	29.59	200,000	5,918,000	1,647,546	Apr 22 06:27 PM
Gline Matthew	CEO	Apr 16 '26	Sale	29.16	289,774	8,449,810	16,736,116	Apr 20 06:27 PM
Venker Eric	Officer	Apr 20 '26	Proposed Sale	29.59	200,000	5,917,135		Apr 20 04:17 PM
Gline Matthew	Officer	Apr 16 '26	Proposed Sale	29.16	289,774	8,449,876		Apr 16 04:33 PM
Humes Jennifer	Chief Accounting Officer	Apr 08 '26	Sale	28.37	13,538	384,073	84,191	Apr 10 06:00 PM
JENNIFER HUMES	Officer	Apr 08 '26	Proposed Sale	28.37	13,538	384,035		Apr 08 04:07 PM
Fitzgerald Meghan	Director	Mar 26 '26	Option Exercise	8.80	70,000	616,000	112,963	Mar 30 09:01 PM
Fitzgerald Meghan	Director	Mar 26 '26	Sale	27.45	70,000	1,921,500	42,963	Mar 30 09:01 PM
MEGHAN FITZGERALD	Director	Mar 26 '26	Proposed Sale	27.45	70,000	1,921,458		Mar 26 04:14 PM
Venker Eric	President & Immunovant CEO	Mar 17 '26	Option Exercise	3.85	200,000	770,000	1,847,546	Mar 19 06:36 PM
Venker Eric	President & Immunovant CEO	Mar 17 '26	Sale	28.24	200,000	5,648,000	1,647,546	Mar 19 06:36 PM
Epperly Melissa B,	Director	Mar 16 '26	Sale	28.68	41,861	1,200,573	15,804	Mar 18 06:23 PM
Venker Eric	Officer	Mar 17 '26	Proposed Sale	28.24	200,000	5,648,836		Mar 17 04:17 PM
MELISSA B EPPERLY	Director	Mar 16 '26	Proposed Sale	28.68	41,861	1,200,498		Mar 16 04:04 PM
Torti Frank	President and Vant Chair	Feb 19 '26	Option Exercise	3.85	1,400,000	5,390,000	15,136,547	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 20 '26	Option Exercise	3.85	1,012,610	3,898,548	14,749,157	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 23 '26	Option Exercise	3.85	587,390	2,261,452	14,323,937	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 19 '26	Sale	27.42	1,400,000	38,388,000	13,736,547	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 20 '26	Sale	27.15	1,012,610	27,492,362	13,736,547	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 23 '26	Sale	27.51	587,390	16,159,099	13,736,547	Feb 23 08:40 PM
FRANK TORTI	Officer	Feb 20 '26	Proposed Sale	27.52	1,600,000	44,032,000		Feb 20 04:29 PM
FRANK TORTI	Officer	Feb 19 '26	Proposed Sale	27.48	1,400,000	38,472,000		Feb 19 04:24 PM
Venker Eric	President & Immunovant CEO	Feb 13 '26	Option Exercise	3.85	200,000	770,000	1,854,597	Feb 18 05:57 PM
Venker Eric	President & Immunovant CEO	Feb 13 '26	Sale	26.49	200,000	5,298,000	1,654,597	Feb 18 05:57 PM
MANCHESTER KEITH S	Director	Feb 12 '26	Sale	26.75	425,000	11,367,000	15,503,113	Feb 13 09:02 PM
MANCHESTER KEITH S	Director	Feb 11 '26	Sale	26.67	425,000	11,334,750	15,928,113	Feb 13 09:02 PM
MANCHESTER KEITH S	Director	Feb 13 '26	Sale	26.50	375,784	9,956,768	15,127,329	Feb 13 09:02 PM
Gold Daniel Allen	Director	Feb 12 '26	Sale	26.75	425,000	11,367,000	15,503,113	Feb 13 09:00 PM
Gold Daniel Allen	Director	Feb 11 '26	Sale	26.67	425,000	11,334,750	15,928,113	Feb 13 09:00 PM
Gold Daniel Allen	Director	Feb 13 '26	Sale	26.50	375,784	9,956,768	15,127,329	Feb 13 09:00 PM
QVT Financial LP	Director by Deputization	Feb 12 '26	Sale	26.75	425,000	11,367,000	15,503,113	Feb 13 08:45 PM
QVT Financial LP	Director by Deputization	Feb 11 '26	Sale	26.67	425,000	11,334,750	15,928,113	Feb 13 08:45 PM
QVT Financial LP	Director by Deputization	Feb 13 '26	Sale	26.50	375,784	9,956,768	15,127,329	Feb 13 08:45 PM
Venker Eric	Officer	Feb 13 '26	Proposed Sale	26.49	200,000	5,298,373		Feb 13 04:21 PM
Sukhatme Mayukh	President & CIO	Feb 09 '26	Option Exercise	12.68	651,558	8,261,755	19,488,105	Feb 11 05:53 PM
Sukhatme Mayukh	President & CIO	Feb 09 '26	Sale	26.47	339,441	8,985,003	19,148,664	Feb 11 05:53 PM

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

CEO & DirectorMr. Matthew Gline

Pharm.D.Dr. Eric Venker M.D.

PresidentDr. Mayukh Sukhatme M.D.

M.D.Dr. Frank M. Torti M.B.A.

Chief Financial OfficerMr. Richard Pulik

CPNG

Coupang Inc

ROIV

Roivant Sciences Ltd

Upgrade your Finviz experience